Eddy Edson
Well-Known Member
- Relationship to Diabetes
- Type 2
A brief nuanced review just published in the European Heart Journal:
In conclusion, contemporary evidence tends to support the notion that lipid-lowering therapy with statins does not significantly alter cognitive function in medium-term studies. Long-term studies (≥10 years of follow-up) are currently pending, however, their implementation is of paramount importance. One of the key challenges in observational studies constitutes the potential of an indication bias, which can be partly addressed by controlling for known risk factors and markers of a healthy lifestyle. Other important issues include the capability of different statins to penetrate the blood-brain barrier based on their lipophilicity, as well as the selection of an optimal dose (low-dose vs. high-dose statin therapy). The latter remains a subject of debate and requires further investigation. Finally, a careful stratification approach to predict the underlying CVD risk in elderly patients is critical, given that cardiovascular benefits of lipid-lowering therapy clearly outweigh the risks associated with potential short-term cognitive detriment. Along this line, advanced imaging tools may help identify patients at risk and guide appropriate preventive strategies, particularly if concerns of statin-associated cognitive detriment are substantiated. While evidence to date remains controversial, the vast amount of available data facilitates the planning of future studies that should aim at better delineating the link between lipid-lowering therapy and neurocognitive function.
Lipid-lowering therapy and the risk of dementia: lessons learned from two decades of controversy
Lipid-lowering agents constitute a cornerstone of cardiovascular disease (CVD) prevention. As such, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (
academic.oup.com
In conclusion, contemporary evidence tends to support the notion that lipid-lowering therapy with statins does not significantly alter cognitive function in medium-term studies. Long-term studies (≥10 years of follow-up) are currently pending, however, their implementation is of paramount importance. One of the key challenges in observational studies constitutes the potential of an indication bias, which can be partly addressed by controlling for known risk factors and markers of a healthy lifestyle. Other important issues include the capability of different statins to penetrate the blood-brain barrier based on their lipophilicity, as well as the selection of an optimal dose (low-dose vs. high-dose statin therapy). The latter remains a subject of debate and requires further investigation. Finally, a careful stratification approach to predict the underlying CVD risk in elderly patients is critical, given that cardiovascular benefits of lipid-lowering therapy clearly outweigh the risks associated with potential short-term cognitive detriment. Along this line, advanced imaging tools may help identify patients at risk and guide appropriate preventive strategies, particularly if concerns of statin-associated cognitive detriment are substantiated. While evidence to date remains controversial, the vast amount of available data facilitates the planning of future studies that should aim at better delineating the link between lipid-lowering therapy and neurocognitive function.